Oncology

MedTech News and Updates for Olympus, GE, Journey Biosciences, NeuroOne, Enovis

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Olympus Launches New Gynecologic Power Morcellator; Journey Biosciences Launched NaviDKD; GE Board Approves Separation of GE HealthCare; FDA Approval to Enovis’s STAR Ankle; FDA Clearance to Deep Blue Medical’s T-Line Hernia Mesh; NeuroOne Completed Feasibility Study with its OneRF Ablation System

Olympus Launches New Gynecologic Power Morcellator for Its Contained Tissue Extraction System On November 30, 2022, Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, launched the moresolution™ Power Morcellator, manufactured by TROKAMED GmbH and available in the U.S. through a distribution agreement with Olympus America, Inc. The moresolution™ Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens. The Olympus Contained Tissue Extraction System includes the PneumoLiner™, a first-of-its-kind containment device, and the mor...

Explore More...

Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab’s result; Orca raises $192M

Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL

One of the leading causes of blindness, and a sight-threatening disease, Uveitis, now has novel treatment approaches in its pipeline

Precision Medicine: An emerging approach to conventional treatment

Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ’s anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost

Altering the course of Ovarian cancer with emerging therapies in the horizon

Neoantigen based Personalized Cancer Therapeutic Vaccines Market

Changing the Paradigm of Cancer: Neoantigen based Personalized Cancer Therapeutic Vaccines

Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19

Soft Tissue Sarcoma Market Size and Forecast

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Oncology

Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab’s result; Orca raises $192M

Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL

One of the leading causes of blindness, and a sight-threatening disease, Uveitis, now has novel treatment approaches in its pipeline

Precision Medicine: An emerging approach to conventional treatment

Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ’s anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost

Altering the course of Ovarian cancer with emerging therapies in the horizon

Changing the Paradigm of Cancer: Neoantigen based Personalized Cancer Therapeutic Vaccines

Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19

More Views & Analysis

Soft Tissue Sarcoma Market size to increase with a CAGR of 6.47% – Emerging therapies and Increasing Incidence form major market drivers

JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19

Soft Tissue Sarcoma Treatment Market: Present treatment approaches and Unmet Needs

Soft Tissue Sarcoma: A rare malignancy

Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust

J&J collaborates with BARDA; Virus kills pancreatic cancer cells; ALX raises USD 105 million for CD47 drug

Good news for Kite’s KTE-X19, and Aquestive’s Libervant; and a commercialization deal between ReForm Biologics, MilliporeSigma

First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed’s shares Soares

Subscribe to our Updates

Daily

Weekly

Monthly